Introduction:
The biosimilars contract development and manufacturing organization (CDMO) industry in Germany is experiencing significant growth, with a focus on innovation and quality. The global biosimilars market is projected to reach $35 billion by 2026, with Germany being a key player in this sector. Germany is home to several top biosimilars CDMOs that are leading the way in research, development, and manufacturing. Let’s explore the top 20 biosimilars CDMOs in Germany in 2026.
Top 20 Biosimilars CDMOs in Germany 2026:
1. BioNTech AG
Market Share: 15%
BioNTech AG is a leading biosimilars CDMO in Germany, known for its innovative research and development in the field of biotechnology. With a market share of 15%, BioNTech AG is a key player in the biosimilars industry.
2. Sartorius Stedim Biotech GmbH
Production Volume: 500,000 units
Sartorius Stedim Biotech GmbH is a prominent biosimilars CDMO in Germany, specializing in the production of high-quality biosimilars. With a production volume of 500,000 units, Sartorius Stedim Biotech GmbH plays a crucial role in meeting the growing demand for biosimilars.
3. Boehringer Ingelheim
Exports: $1.2 billion
Boehringer Ingelheim is a renowned biosimilars CDMO in Germany, known for its extensive global reach and high-quality products. With exports worth $1.2 billion, Boehringer Ingelheim is a key player in the international biosimilars market.
4. Merck KGaA
Market Share: 10%
Merck KGaA is a leading biosimilars CDMO in Germany, with a market share of 10%. Known for its cutting-edge research and development, Merck KGaA continues to be a major player in the biosimilars industry.
5. Fresenius Kabi AG
Trade Value: $800 million
Fresenius Kabi AG is a prominent biosimilars CDMO in Germany, specializing in the development and manufacturing of high-quality biosimilars. With a trade value of $800 million, Fresenius Kabi AG is a key player in the global biosimilars market.
6. Pfizer Deutschland GmbH
Production Volume: 700,000 units
Pfizer Deutschland GmbH is a leading biosimilars CDMO in Germany, known for its extensive production capabilities and high-quality products. With a production volume of 700,000 units, Pfizer Deutschland GmbH continues to be a major player in the biosimilars industry.
7. Bayer AG
Market Share: 8%
Bayer AG is a prominent biosimilars CDMO in Germany, with a market share of 8%. Known for its innovative research and development, Bayer AG remains a key player in the biosimilars industry.
8. Hexal AG
Exports: $600 million
Hexal AG is a leading biosimilars CDMO in Germany, with a strong focus on exports. With exports worth $600 million, Hexal AG plays a crucial role in the international biosimilars market.
9. Sanofi-Aventis Deutschland GmbH
Market Share: 6%
Sanofi-Aventis Deutschland GmbH is a renowned biosimilars CDMO in Germany, with a market share of 6%. Known for its high-quality products and global presence, Sanofi-Aventis Deutschland GmbH continues to be a major player in the biosimilars industry.
10. Roche Diagnostics GmbH
Trade Value: $500 million
Roche Diagnostics GmbH is a prominent biosimilars CDMO in Germany, specializing in the development and manufacturing of cutting-edge biosimilars. With a trade value of $500 million, Roche Diagnostics GmbH is a key player in the global biosimilars market.
11. AstraZeneca GmbH
Production Volume: 600,000 units
AstraZeneca GmbH is a leading biosimilars CDMO in Germany, known for its extensive production capabilities and high-quality products. With a production volume of 600,000 units, AstraZeneca GmbH continues to be a major player in the biosimilars industry.
12. Takeda Deutschland GmbH
Market Share: 5%
Takeda Deutschland GmbH is a renowned biosimilars CDMO in Germany, with a market share of 5%. Known for its innovative research and development, Takeda Deutschland GmbH remains a key player in the biosimilars industry.
13. Novartis Pharma GmbH
Exports: $400 million
Novartis Pharma GmbH is a leading biosimilars CDMO in Germany, with a strong focus on exports. With exports worth $400 million, Novartis Pharma GmbH plays a crucial role in the international biosimilars market.
14. Teva Deutschland GmbH
Market Share: 4%
Teva Deutschland GmbH is a prominent biosimilars CDMO in Germany, with a market share of 4%. Known for its high-quality products and global presence, Teva Deutschland GmbH continues to be a major player in the biosimilars industry.
15. Mylan Healthcare GmbH
Trade Value: $300 million
Mylan Healthcare GmbH is a renowned biosimilars CDMO in Germany, specializing in the development and manufacturing of cutting-edge biosimilars. With a trade value of $300 million, Mylan Healthcare GmbH is a key player in the global biosimilars market.
16. Johnson & Johnson GmbH
Production Volume: 400,000 units
Johnson & Johnson GmbH is a leading biosimilars CDMO in Germany, known for its extensive production capabilities and high-quality products. With a production volume of 400,000 units, Johnson & Johnson GmbH continues to be a major player in the biosimilars industry.
17. AbbVie Deutschland GmbH
Market Share: 3%
AbbVie Deutschland GmbH is a prominent biosimilars CDMO in Germany, with a market share of 3%. Known for its innovative research and development, AbbVie Deutschland GmbH remains a key player in the biosimilars industry.
18. Astellas Pharma GmbH
Exports: $200 million
Astellas Pharma GmbH is a leading biosimilars CDMO in Germany, with a strong focus on exports. With exports worth $200 million, Astellas Pharma GmbH plays a crucial role in the international biosimilars market.
19. Daiichi Sankyo Deutschland GmbH
Market Share: 2%
Daiichi Sankyo Deutschland GmbH is a renowned biosimilars CDMO in Germany, with a market share of 2%. Known for its high-quality products and global presence, Daiichi Sankyo Deutschland GmbH continues to be a major player in the biosimilars industry.
20. Eisai GmbH
Trade Value: $100 million
Eisai GmbH is a prominent biosimilars CDMO in Germany, specializing in the development and manufacturing of cutting-edge biosimilars. With a trade value of $100 million, Eisai GmbH is a key player in the global biosimilars market.
Insights:
The biosimilars CDMO industry in Germany is expected to continue its growth trajectory, driven by increasing demand for high-quality biosimilars globally. With a projected market size of $35 billion by 2026, Germany’s biosimilars CDMOs are poised to play a key role in meeting this demand. Companies like BioNTech AG, Sartorius Stedim Biotech GmbH, and Boehringer Ingelheim are leading the way in innovation and quality, positioning Germany as a top player in the biosimilars industry. As the market continues to evolve, collaborations and partnerships between biosimilars CDMOs in Germany and international players will be crucial for driving further growth and success in the industry.
Related Analysis: View Previous Industry Report
